Cadila to Launch its Ritucad (rituximab- biosimilar) in India
Shots:
- Cadila to strengthen its biosimilar portfolio and oncology footprints in India with the launch of Ritucad and has cleared USFDA inspection in Feb’20
- Additionally- the company has launched its Bevaro (bevasizumab- biosimilar) a mAb targeted for multiple cancer indications like Ovarian Cancer- Glioblastoma Multiforme (a type of Brain cancer)- Colorectal Cancer- Breast Cancer- Lung Cancer- Cervical Cancer and Kidney Cancer in India
- Ritucad is the second biosimilar in Cadila’s portfolio of biosimilars and will be available in a single-dose vial of two strengths- 100 mg & 500mg targeted to treat Non-Hodgkin’s lymphoma and RA
Ref: Cadila | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
